Department of Internal Medicine, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, The Netherlands.
Department of Cardiology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, The Netherlands.
Cardiovasc Intervent Radiol. 2019 Jul;42(7):962-969. doi: 10.1007/s00270-019-02200-1. Epub 2019 Mar 12.
To provide insight into the current use and results of ultrasound-facilitated catheter-directed thrombolysis (USAT) in patients with high-risk pulmonary embolism (PE).
Systemic thrombolysis is an effective treatment for hemodynamically unstable, high-risk PE, but is associated with bleeding complications. USAT is thought to reduce bleeding and is therefore advocated in patients with high-risk PE and contraindications for systemic thrombolysis.
We conducted a retrospective cohort study of all patients who underwent USAT for high-risk PE in the Netherlands from 2010 to 2017. Characteristics and outcomes were analyzed. Primary outcomes were major (including intracranial and fatal) bleeding and all-cause mortality after 1 month. Secondary outcomes were all-cause mortality and recurrent venous thromboembolism within 3 months.
33 patients underwent USAT for high-risk PE. Major bleeding occurred in 12 patients (36%, 95% CI 22-53), including 1 intracranial and 3 fatal bleeding. All-cause mortality after 1 month was 48% (16/33, 95% CI 31-66). All-cause mortality after 3 months was 50% (16/32, 95% CI 34-66), recurrent venous thromboembolism occurred in 1 patient (1/32, 3%, 95% CI 1-16).
This study was the first to describe characteristics and outcomes after USAT in a study population of patients with high-risk PE only, an understudied population. Although USAT is considered a relatively safe treatment option, our results illustrate that at least caution is needed in critically ill patients with high-risk PE. Further research in patients with high-risk PE is warranted to guide patient selection.
深入了解超声引导下导管溶栓术(USAT)在高危肺栓塞(PE)患者中的应用现状和效果。
全身溶栓治疗对血流动力学不稳定、高危 PE 是一种有效的治疗方法,但与出血并发症相关。USAT 被认为可减少出血,因此在有全身溶栓治疗禁忌证的高危 PE 患者中被提倡。
我们对 2010 年至 2017 年期间在荷兰接受 USAT 治疗高危 PE 的所有患者进行了回顾性队列研究。分析了特征和结局。主要结局为 1 个月后主要(包括颅内和致命性)出血和全因死亡率。次要结局为 3 个月内全因死亡率和复发性静脉血栓栓塞症。
33 例患者因高危 PE 接受 USAT。12 例(36%,95%CI 22-53)患者发生主要出血,包括 1 例颅内出血和 3 例致命性出血。1 个月时的全因死亡率为 48%(16/33,95%CI 31-66)。3 个月时的全因死亡率为 50%(16/32,95%CI 34-66),1 例(1/32,3%,95%CI 1-16)患者复发静脉血栓栓塞症。
本研究首次在仅高危 PE 患者的研究人群中描述了 USAT 后的特征和结局,这是一个研究较少的人群。尽管 USAT 被认为是一种相对安全的治疗选择,但我们的结果表明,在高危 PE 的危重症患者中至少需要谨慎。需要进一步研究高危 PE 患者,以指导患者选择。